Supernus Pharmaceuticals Inc
LSE:0LB2
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Supernus Pharmaceuticals Inc
LSE:0LB2
|
US |
|
S
|
Stevia Nutra Corp
OTC:STNT
|
CA |
|
F
|
Franklin Resources Inc
BMV:BEN
|
US |
|
H
|
Huron Consulting Group Inc
XBER:HUR
|
US |
Wall Street
Price Targets
0LB2 Price Targets Summary
Supernus Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
0LB2
is 64.02 USD
with a low forecast of 55.63 USD and a high forecast of 69.4 USD.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is 0LB2's stock price target?
Price Target
64.02
USD
According to Wall Street analysts, the average 1-year price target for
0LB2
is 64.02 USD
with a low forecast of 55.63 USD and a high forecast of 69.4 USD.
What is Supernus Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
8%
For the last 14 years the
compound annual growth rate for
Supernus Pharmaceuticals Inc's revenue is
63%.
The projected
CAGR
for the next 8 years is
8%.
What is Supernus Pharmaceuticals Inc's Operating Income forecast?
Projected CAGR
62%
The
compound annual growth rate
of Supernus Pharmaceuticals Inc's operating income for the next 8 years is
62%.
